Nurix Therapeutics, Inc. (NRIX)
Valuation Overview•Is Nurix Therapeutics, Inc. Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
High-quality fundamentals with a strong composite quality score of 79/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Solid fundamental quality, though growth presents a headwind.
Wall Street is highly bullish, projecting significant upside. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
NRIX exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins. This is backed by a fortress balance sheet, holding significant net cash ($191M) and minimal debt risk.
The company is driving exceptional top-line expansion (29.5% 3Y CAGR) paired with stable bottom-line earnings. This growth is supported by elite operational efficiency, sustaining an impressive 41.3% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $673.1M | +54.0% | +29.5% | +36.3% | — | |
| EBITDA | $561.6M | — | -15.5% | — | — | |
| Net Income | $549.8M | -36.6% | -13.6% | — | — | |
| EPS (Diluted) | $4.73 | -5.9% | — | — | — | |
| Free Cash Flow | $614.2M | -44.9% | -15.3% | -124.4% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 86.5% | -124.8% | -208.7% | -171.2% |
| Operating Margin | 41.3% | -310.7% | -360.9% | -283.3% |
| Net Margin | 42.0% | -285.6% | -343.5% | -256.9% |
| FCF Margin | 52.7% | -254.6% | -302.3% | -203.7% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q4'26Latest | $-0.60 | $4.73 | +887.1% | ||
| Q3'26 | $-0.72 | $-0.81 | -12.1% | ||
| Q2'26 | $-0.76 | $-0.79 | -3.9% | ||
| Q1'26 | $-0.84 | $-0.82 | +2.4% | ||
| Q4'25 | $-0.84 | $-1.03 | -22.6% | ||
| Q3'25 | $-0.71 | $-0.52 | +26.8% | ||
| Q2'25 | $-0.72 | $-0.67 | +6.9% | ||
| Q1'25 | $-0.67 | $-0.75 | -11.9% |
Total return is +22.2% (1Y), outperforming the benchmark by +12.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -15.3% | -22.9% | — |
| 1Y | +22.2% | +12.5% | — |
| 3YCAGR | +37.3% | +16.9% | — |
| 5YCAGR | -14.5% | -24.4% | — |
| 10YCAGR | -2.1% | -15.6% | — |
The S&P 500 is at 29.9x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Nurix Therapeutics, Inc. (NRIX) valuation, health, and returns.
Nurix Therapeutics, Inc. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +466.9% upside to DCF intrinsic value of $86.73)
Nurix Therapeutics, Inc. has multiple valuation anchors: DCF Intrinsic Value: $86.73 | Peer Relative Fair Value: $134.18 | Wall Street Analyst Target: $33.69 (implying +120.2% upside). A convergence of these signals offers higher conviction.
Nurix Therapeutics, Inc. displays good financial health with a composite quality score of 79/100, supported by a Altman Z-Score of 3.7 (safe zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of -54.0%.
Nurix Therapeutics, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Nurix Therapeutics, Inc.'s current growth trajectory is Accelerating. The company achieved +54.0% 1Y revenue growth and -5.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +29.5%.
Wall Street consensus is Buy based on 19 analysts, beating EPS expectations in 42% of recent quarters with a 1-quarter streak. The consensus price target represents a +120.2% change from current levels.
Investment risks for Nurix Therapeutics, Inc. include: -46.6% 1-year max drawdown. Volatility risk is characterized by a beta of 0.95x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.